A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 1, 1998, Pages 356-361

  Ferguson, Ronald J ^a,g   De Morais, Sonia M F ^a,h   Benhamou, Simone ^b   Bouchardy, Christine ^c   Blaisdell, Joyce ^a   Ibeanu, Gordon ^a   Wilkinson, Grant R ^d   Sarich, Troy C ⁱ   Wright, James M ^e   Dayer, Pierre ^f   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b INSERM   (France)

^c GENEVA CANCER REGISTRY   (Switzerland)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g UNIVERSITY OF FLORIDA   (United States)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

ⁱ NIEHS ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 CYP 2 C 19; CYTOCHROME P450 ISOENZYME; MEPHENYTOIN; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CAUCASIAN; CONTROLLED STUDY; DRUG METABOLISM; GENE FREQUENCY; GENE MUTATION; HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; POOR METABOLIZER PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; START CODON;

ALLELES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CODON; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; MUTATION;

EID: 15444340367     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Adedoyin A, Prakash C, O'Shea D, Blair IA and Wilkinson GR (1994) Stereo selective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin nolymorphism in Caucasian and Chinese subjects. Pharmacogenetics 4:27-38.
2. Andersson T, Regardh C-G, Lou Y-C, Zhang Y, Dahl ML and Bertilsson L (1992) Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2:25-31.
3. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K (eds) (1990) Current Protocols in Molecular Biology, vol. 2, pp 13.2.1-13.2.2, John Wiley & Sons, Inc., New York, NY.
4. Balian JD, Sukhova N, Harris JW, Hewett J, Pickel L, Goldstein JA, Woosley RL and Flockhart DA (1995) The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 57:662-669.
5. Baumann P, Jonzier-Perez M, Kerb L, Küpfer A, Tingueley D and Schöpf J (1986) Amitriptyline pharmacokinetics and clinical response. II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1:102-112.
6. Benhamou S, Bouchardy C and Dayer P (1997) Lung cancer risk in relation to mephenytoin hydroxylation activity. Pharmacogenetics 7:157-159.
7. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J and Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 45:348-355.
8. Brøsen K, deMorais SMF, Meyer UA and Goldstein JA (1995) A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 5:312-317.
9. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Meyer UA, Nebert DW, Steen VM, Wolf CR, and Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201.
10. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA and Goldstein JA (1994b) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598.
11. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA and Goldstein JA (1994a) The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 269:15419-15422.
12. 180 →Cys) determines the polymorphism in cytochrome P450g (P4502C13) by altering protein stability. J Biol Chem 267:2032-2037.
13. Goldstein JA and Blaisdell J (1996) Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 272:210-217.
14. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM and Ghanayem BI (1994) Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 33:1743-1752.
15. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM and Price Evans D (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American Black populations. Pharmacogenetics 7:59-64.
16. Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA and Wedlund PJ (1990) Rapid screening for polymorphism in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol 29:373-380.
17. Hahn GJ and Meeker WQ (1991) Statistical Intervals: A Guide for Practitioners, pp 104-105, John Wiley & Sons, Inc., New York.
18. Isashiki Y. Ohba N, Yanagita T, Hokita N, Doi N, Nakagawa M, Ozawa M and Kuroda N (1995) Novel mutation at the initiation codon in the Norrie disease gene in two Japanese families. Human Genet 95:105-108.
19. Küpfer A and Branch RA (1985) Stereo selective mephobarbital hydroxylation co-segregates with mephenytoin hydroxylation. Clin Pharmacol Ther 38:414-418.
20. Küpfer A and Preisig R (1984) Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753-759.
21. Meier UT, Dayer P, Malé PJ, Kronbach T and Meyer UA (1985) Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther 38: 488-494.
22. Nielsen KK, Brøsen K, Hansen J and Gram LF (1994) Single-dose kinetics of clomipramine: relationship to the sparteine/debrisoquine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 55:518-527.
23. Patten JL, Johns DR, Valle D, Eil C, Gruppuso PA, Steele G, Smallwood P and Levine MA (1990) Mutation in the gene encoding the stimulatory g protein of adenylate cyclase in Albright's hereditary osteodystrophy. N Engl J Med 322: 1412-1419.
24. Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ and Johnson EF (1995) A universal approach to the expression of human and rabbit cytochrome P450 of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 323:87-96.
25. Romkes M, Faletto MB, Blaisdell JA, Raucy JL and Goldstein JA (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30:3247-3255.
26. Sambrook J, Fritsch EF and Maniatis T (1989) Isolation of high-molecular-weight DNA from mammalian cells, in Molecular Cloning: A Laboratory Manual. 2nd ed, pp 9.16-9.18, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
27. Sarich TC, Kalhorn T, Magee S, AlSayeh F, Adams S, Slattery J, Goldstein J, Nelson S and Wright J (1997) The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharmacol Ther 62:21-28.
28. Shaw GC and Fulco AJ (1992) Barbiturate-mediated regulation of expression of the cytochrome P450 BM-3 gene of Bacillus megaterium by BM3R1 protein. J Biol Chem 267:5515-5526.
29. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jorgensen T, Overo KF and Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 13:11-17.
30. Skjelbo E, Brøsen K, Hallas J and Gram LF (1991) The mephenytoin oxidative polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49:18-23.
31. Sugihara H, Andrisani V and Salvaterra PM (1990) Drosophila choline acetyl transferase uses a non AUG initiation codon and full length RNA is inefficiently translated. J Biol Chem 265:21714-21719.
32. Wang SL, Huang JD, Lai MD and Tsai JJ (1995) Detection of CYP2C9 polymorphism based on polymerase chain reaction in Chinese. Pharmacogenetics 5:37-42.
33. Ward SA, Walle T, Walle UK, Wilkinson GR and Branch RA (1989) Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin Pharmacol Ther 45:72-79.
34. Ward SA, Helsby NA, Skejlbo E, Brøsen K, Gram LF and Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism: A panel study. Br J Clin Pharmacol 31: 689-692.
35. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA and Wilkinson GR (1984) Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr B Biomed Appl 121-127.
36. Wedlund PJ, Sweetman BJ, Wilkinson GR and Branch RA (1987) Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 15:277-279.
37. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR and Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug polymorphism. Clin Pharmacol Ther 36:773-780.
38. Wilkinson GR, Guengerich FP and Branch RA (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43:53-76.
39. Wrighton SA, Stevens JC, Becker GW and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240-245.
40. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J and Wedlund PJ (1992) Limitation to the use of urinary S/R mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 31:350-352.